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Summanr P450 reductase (NADPH:cy-tochrome P450 reductase. EC 1.6.2.4) is known to be important in the
reductive activation of the benzotriazene-di-N-oxide tirapazamine (SR 4233). Using a panel of six human
breast adenocarcinoma cell lines we have examined the relationship between P450 reductase activity and
sensitivity to tirapazamine. The toxicity of tirapazamine was found to correlate strongly with P450 reductase
activity following an acute (3 h) exposure under hypoxic conditions, the drug being most toxic in the cell lines
with the highest P450 reductase activity. A similar correlation was also observed following a chronic (96 h)
exposure to the drug in air but not following acute (3 h) exposure in air. We have also determined the ability
of lysates prepared from the cell lines to 'metabolise tirapazamine to its two-electron reduced product, SR
4317. under hypoxic conditions using NADPH as an electron donor. The rate of SR 4317 formation was
found to correlate both with P450 reductase activity and with sensitivity to tirapazamine. the highest rates of
SR 4317 formation being associated with the highest levels of P450 reductase activity and the greatest
sensitivity to the drug. These findings indicate a major role for P450 reductase in determining the hypoxic
toxicity of tirapazamine in breast tumour cell lines.
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The presence of regions of low oxygen tension in a variety of
human solid tumours is now well established (Gatenby et al.,
1988; Hockel et al., 1991: Vaupel et at., 1991; Lartigau et al..
1992) and this hypoxia can predispose to failure of some
treatments with radiotherapy (Gatenby et al.. 1988; Hockel et
al.. 1993: Okumneff et al.. 1993). The resistance of hypoxic
cells to radiation has long been recognised in experimental
systems (Moulder and Rockwell, 1987: Rockwell and
Moulder. 1990), and methods designed to overcome this
resistance have included the development of hypoxic cell
radiosensitisers (Adams, 1976: Stratford, 1992) and more
recently the combination of nicotinamide and carbogen
(Chaplin et al.. 1991). An alternative strategy has been to
develop agents that selectively kill hypoxic cells (Adams and
Stratford, 1986; Stratford et al., 1986; Zeman et al., 1986;
Kennedy, 1987). This approach involves the exploitation of
various biochemical processes that can result in selective
reductive activation of drugs at low oxygen tensions (Ken-
nedy. 1987; Workman. 1992; Workman and Stratford, 1993).
In principle, this concept was first proposed in the context of
quinone bioreductive drugs, with the notion that the low
levels of oxygen in solid tumours could allow reductive
activation of a drug to give a product which was more toxic
than the parent compound (Lin et al., 1972). Subsequently.
agents have been identified that are substantially more toxic
to hypoxic compared with oxic cells and this is the basis for
their tumour selectivity (Adams and Stratford, 1986. 1994;
Stratford and Stephens. 1989.) Classes of compound that are
in, or are about to enter, clinical trial as bioreductive drugs
include (1) RB6145, the lead compound from a series of
dual-function, alkylating nitroimidazoles (Cole et al., 1990,
1991, 1992; Jenkins et al., 1990) (2) quinones such as the
mitomycin C analogue porfiromycin (Rockwell et al., 1988)
and the indoloquinone E09 (Hendriks et al.. 1993); and (3)
the benzotnrazene-di-N-oxide tirapazamine (SR4233, WIN-
59075) (Brown and Lemmon, 1990; Brown, 1993).
As indicated above, the major rationale for the develop-
ment of bioreductive drugs has been the presence of tumour
hypoxia. However, for these agents to be effective they
require metabolic activation. catalysed by the cellular comp-
lement of reductase enzymes. These can include isozymes of
the P450 system, cytochrome P450 reductase, cytochrome b5
reductase, xanthine oxidase etc (Walton et al., 1989; Work-
man. 1992; Hodnick and Sartorelli, 1993). Therefore, it has
been proposed that hypoxic cells could be more effectively
targeted if differences in the levels of reductases in vanrous
cell types were taken into account in order to direct appro-
priate agents to particular human tumours based on their
enzymology (Workman and Walton, 1986; Workman and
Stratford, 1993; Workman, 1994).
The potential usefulness of the 'enzyme-directed' approach
to bioreductive drug development has been very clearly dem-
onstrated with the mitosense E09. The toxicity of this agent
in air is highly dependent on the cellular expression of the
obligate two-electron reductase, DT-diaphorase, (Robertson
et al., 1992, 1994; Plumb et al., 1994; Smitskamp-Wilms et
al., 1994). Under hypoxic conditions, reduction of E09 can
also be catalysed by cytochrome P450 reductase (Bailey et
al., 1994) an enzyme which has been shown to play an
important role in the metabolism of 2-nitroimidazoles (Wal-
ton and Workman, 1987) and N-oxides such as tirapazamine
(Walton et al., 1989).
In previous studies on the metabolism of tirapazamine
using mouse and rat liver microsomes (Walton et al., 1989,
1992; Lloyd et al., 1991) and tumour cell lysates (Wang et al.,
1993) it was shown that both cytochrome P450 and cytoch-
rome P450 reductase contribute to the overall reduction of
tirapazamine to its two-electron reduced product SR 4317.
Cytochrome P450 is dependent upon the presence of cytoch-
rome P450 reductase for its catalytic activity (Peterson and
Prough, 1986). Hence, P450 reductase will play both direct
and indirect roles in the reduction of tirapazamine. More-
over, tirapazamine is reduced by purified rat liver cytochrome
P450 reductase (Walton et al., 1989, Cahill and White, 1990)
leading to the production of strand breaks in co-incubated
plasmid DNA (Fitzsimmons et al., 1994). Therefore, the aim
of this work was to assess the likely importance of P450
reductase activity for determining the sensitivity of tumour
cells to tirapazamine. To do this we have measured P450
reductase activity in a panel of six human breast adenocar-
cinoma cell lines, and compared this with their sensitivity to
tirapazamine under hypoxic and aerobic conditions. Given
the role of P450 reductase in reducing tirapazamine, we have
also determined the ability of the different cell lines to
metabolise tirapazamine to its reduced product SR 4317
un*er hypoxic conditions.
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Chemicals
Tirapazamine, SR 4317 and SR 4330 were obtained from
Sterling Winthrop Ltd or synthesised in house using pre-
viously described methods (Seng and Ley, 1972). NADPH
was purchased from Boehnrnger Mannheim (Lewes, UK),
HPLC-grade methanol was purchased from Merck (Lutter-
worth, UK). All other reagents were of analytical grade and
were purchased from Sigma (Poole, UK). Tissue culture
medium was obtained from ICRF (Clair Hall Labs, UK) and
fetal calf serum from Sigma.
Cells and culture
Table I lists the six human breast tumour cell lines used in
this work. All cell lines were maintained in exponential
growth phase in RPMI-1640 medium (except for SKBr-3
cells which were maintained in E4 medium), supplemented
with 2 mM glutamine and 10% (v/v) fetal calf serum. MCF-7
(EP) cells are early passage cells (passage 60-70) from the
original strain established by Soule et al. (1973). In one set of
experiments, indicated by footnote d in Table I, a late pas-
sage strain of MCF-7 cells was used (Newcastle Strain,
MCF-7 (LP), passage> 300). Measurements of P450 reduc-
tase activity were made in each strain and showed no
significant difference.
Drug sensitivity
Dose-response curves were determined using the MTT pro-
liferation assay. which is based on the ability of viable cells
to convert a soluble tetrazolium salt, MTT. into purple for-
mazan crystals (Mossman. 1983). The optical density of the
dissolved crystals is proportional to the number of viable
cells, although this varies between cell lines as the conversion
of MTT to formazan depends on the level of mitochondrial
dehydrogenase activity in each cell line (Carmichael et al..
1987). The conditions for carrying out the assay have been
described elsewhere (Robertson et al.. 1994; Carmichael et
al.. 1987) and require plating 1 x I0-5 x 103 cells (depen-
ding on cell line) into each well of a 24-well glass dish 3 h
before exposure to tirapazamine for 3 h at 37°C in either air
or hypoxia. The cells were then washed free of drug and
allowed to grow for 4 days in 0.4 ml of fresh medium.
Alternatively, chronic (96 h) aerobic exposures were carried
out in a 96-well-plate format. After 4 days, MIT was added
(0.2 mg ml-' medium) and cells incubated for a further 4 h.
Culture medium and unconverted MTT were removed and
the formazan crystals dissolved in 0.2 ml dimethyl-sulphoxide
(DMSO). An aliquot of 25 glI of glycerine buffer. pH 10.5
(Plumb et al., 1989) was then added and the optical density
at 540 nm measured on a multiwell spectrophotometer.
Values of IC50. the concentration of tirapazamine required to
reduce optical density by 50% compared with the untreated
controls, were used as the measure of cellular sensitivity to a
given treatment. The ICo values quoted in Table I are the
means of at least three independent experiments conducted
on different days.
Cell lv sates
Cells in exponential growth phase were washed twice with
phosphate-buffered saline (PBS) and harvested using a sterile
cell scraper. Following centrifugation at 800 r.p.m. for 8 m.n,
pellets were taken and washed in ice-cold hypotonic nuclear
buffer A (10 mM Hepes potassium hydroxide pH 7.4. 1.5 mM
magnesium chloride. 10 mM potassium chloride. 0.05 mM
DIT). Following repelleting. cells were suspended in 1.5 ml
of nuclear buffer A and allowed to stand for 10 min at 4'C.
Suspensions were sonicated using an MSE Soniprep 150 for
3 x 5 s at a nominal frequency of 23 kHz and an oscillation
amplitude of between 5 and lOm. Samples were placed on
ice between each sonication. The suspensions were allowed to
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stand on ice for a further 10 mn. and then centrifuged at
7800g for 15 mn at 4C. The resulting lysate was removed
and stored in liquid nitrogen until required. The protein
concentration of the cell lysates was determined using the
Bio-Rad protein dye assay (Bradford. 1976) using high-grade
bovine serum albumin (BSA) as the standard.
.NADPH:P450 reductase activity
P450 reductase activity was determined spectrophotometri-
cally as the NADPH-dependent reduction of cytochrome c.
Each incubation comprised 400 tl of the cytochrome c (final
concentration 50 LM). 100 al of 10 mM potassium cyanide
acetonitrile (final concentration 1 mM) and 100-300,.g
lysate protein (50-100 iLl volume) made up to 0.98 ml with
100 mM phosphate buffer. pH 7.6. The reaction was equilib-
rated to 37C and initiated by addition of 20pIl 10 mm
NADPH to the test cuvette (final concentration 200 SAM) and
the rate of reduction of cytochrome c was monitored at
550 nm for 3 min against a blank without NADPH. Initial
rates of reaction were based on an extinction coefficient of
21 mM- cm-l calculated and expressed as nmol cytochrome
c reduced per min permg lysate protein.
Western blot analf(sis
Samples of cells harvested for enzyme assays were washed in
PBS buffer containing 1 mM phenylmethylsulphonyl fluoride.
1 mM benzamide, 50jigml-' leupeptin and 50ILg ml-' soya-
bean trypsin inhibitor. Cells were lysed in 1 ml 2% w v
sodium dodecyl sulphate (SDS), plus inhibitors in PBS at
65°C for 5 min. then suspensions passed up and down a
fine-gauge needle in order to break up the DNA. Samples
were stored at - 20C. Proteins were subsequently resolved
by 7.5% SDS-polyacrylamide gel electrophoresis, and pro-
teins on the gel were electrophoretically transferred overnight
to a nitrocellulose hybridisation transfer membrane. The
membrane was washed with blocking buffer (20 mm Tris-
HCL (pH 7.5), 0.9% sodium chloride, 0.5% Tween 20, 1%
low fat Marvel). and incubated for 60 min with specific
NADPH:P450 reductase rabbit antibody (dilution 1:500. sup-
plied by Professor CR Wolf. University of Dundee, UK).
After washing, horseradish peroxidase-conjugated goat anti-
rabbit antibody (dilution 1:5000) was added and incubated
for 30 min. All antibodies were diluted in blocking buffer.
The membrane was developed using an enhanced
chemiluminescence Western blotting detection kit (Amer-
sham, UK).
Metabolism oftirapazamine b} cell lxvsates
Incubations were carried out under nitrogen at 37°C in 4 ml
amber glass vials (Chromacol. Welwyn Garden City. UK)
sealed with Subaseal (Aldrich. Gillingham, UK). The 500 tlI
incubation volume comprised 100 IlI of cell lysate (maximum
final protein concentration of 1.5 mg ml-'). 100IL of
NADPH (5 mM dissolved in incubation buffer, giving a final
incubation concentration of 1 mm). 20 LI of tirapazamine
(50 mM dissolved in DMSO to give a final incubation con-
centration of 2 mM) and 280 tLI of incubation buffer (0.2 M
potassium phosphate buffer. pH 7.4). After preincubation
under nitrogen for 10 mmn, the reaction was started by addi-
tion of tirapazamine using a Hamilton syringe inserted
through the Subaseal. Reactions were stopped after 40 mmn
by transferring 2 x 200;l aliquots of the incubate into poly-
propylene vials containing 50 gil of internal standard [4-
nitroquinoline N-oxide; 0.4 mg ml-' in 20% (v v) ethanol]
and 400 gd of methanol. Samples were vortexed vigorously
for 2 min. centrifuged for 5 minii at 3000 r.p.m. and 200 IAl
aliquots of the supernatants injected onto the HPLC system
for analysis. Three lysate preparations for each cell line were
incubated, each in duplicate. with duplicate analyses. Forma-
tion of SR 4317 was linear for at least 40min and up to a
protein concentration of 1.5 mgml-. determined usingTwapzum aciviy in brnstcauw cdk
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SkBr3 lysates, which have the highest P450 reductase activity
amongst the panel of cell lines.
HPLC
Concentrations of SR 4317 and SR 4330 in incubation sam-
ples were determined by isocratic reverse phase HPLC (Wal-
ton and Workman, 1990). Chromatography was performed
using a Waters yBondapak phenyl 4pm radial compression
cartridge in a Waters radial compression module (Waters
Chromatography, Watford, UK) and protected with a phenyl
guard column. The mobile phase consisted of 32% methanol
in water delivered at a flow rate of 3 ml min '. Detection was
at 267 nm. Approximate retention times under these condi-
tions were 2.7, 4.6, 5.2 and 8.4 min for tirapazamine,
SR4330, SR4317 and 4-nitroquinoline N-oxide (internal
standard) respectively. Concentrations of metabolites were
calculated from peak height ratios and comparison with
calibration curves (O-500cM) prepared by spiking lysate
preparations with known amounts of metabolite.
Statistical analysis
The data were analysed using the standard model for a linear
functional relationship with sampling errors in both
variables. The data were logarithmically transformed and the
pooled variance ofeach data set was calculated. It is assumed
that the random sampling errors are normally and
independently distributed with zero means and variances
inversely proportional to the sample size. For statistical
analysis of any two data sets, the model is fitted to the
observations by the method of weighted least squares, each
sample mean being weighted in direct proportion to the
sample size. The statistical goodness-of-fit for any two data
sets was tested by calculating the weighted mean-square
deviation of the observations for mean x, and mean y. from
the fitted model, and comparing this mean-square with the
pooled variance within samples by a variance-ratio test. The
statistical significance of the estimate of the slope of the
straight line of best fit was tested by a Student's t-test.
Results
The toxic effect of tirapazamine on the breast cancer cell
lines was determined in two sets of experiments. Firstly, by
exposing cells to drug for 3 h under aerobic or hypoxic
conditions and secondly, by growing cells in air for 96 h in
the presence of tirapazamine. Cytotoxicity was measured by
the MTT assay and typical survival curves, derived from
individual experiments are given in Figure 1. The data illus-
trate the large increase in toxicity that occurs when drug
exposure is under hypoxic compared with aerobic conditions
and also show that the absolute potency of the drug in air
and hypoxia can vary between cell lines. From such curves
values of IC5o can be obtained. Mean values derived from at
least six independent, replicate experiments which update our
previously published data (Patterson et al., 1994) are given in
Table I. (Cell lines are listed in order of sensitivity to
tirapazamine under hypoxic conditions). Also included in the
table are values of differential toxicity. This is the ratio of
IC50 values obtained following 3 h exposure to tirapazamine
in air vs hypoxia. Each cell line is more sensitive to
tirapazamine under hypoxia, with values of differential tox-
icity covering a 5- to 6-fold range from 13 to 69. There is no
relationship between the value of differential toxicity and
drug potency under either aerobic or hypoxic conditions.
The level of NADPH-dependent P450 reductase activity,
measured in lysates from up to four separate cultures of each
cell line, is given in Table I. The enzyme activity in the breast
cancer cell lines covers a 6-fold range. This contrasts with the
activity of the reductase DT-diaphorase in these cell lines,
which varies by a factor of 260, the highest expressor being
ZR-75 and the lowest MDA-231 cells (Robertson et al.,
1994). We have shown previously that the toxicity of
tirapazamine in breast and lung cancer cells following a 96 h
aerobic exposure does not depend on DT-diaphorase activity
(Patterson et al., 1994). However, as can be seen in Figure 2,
there is a clear relationship between P450 reductase activity
and tirapazamine toxicity in breast cancer cells following
chronic (96 h) exposure in air. The highest toxicity (lowest
value of IC50) occurs in the cell line with highest activity of
P450 reductase (SKBr3). The value of slope derived from
these data is- 1.6 ± 0.3 (P= 0.006).
The importance of P450 reductase in the activation and
toxicity of tirapazamine in the breast cancer cells has been
characterised further by carrying out acute (3 h) exposure to
drug under aerobic and hypoxic conditions. The dependence
of IC50 on P450 reductase activity is shown in Figure 3.
Under hypoxic conditions there is a highly significant rela-
tionship between intracellular enzyme activity and drug tox-
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Fue 1 Examples of individual survival curves derived by the
MUT assay for SKBr3 cells (circles) and ZR-75 cells (squares)
exposed to tirapazamine for 3 h under aerobic (closed symbols)
or hypoxic (open symbols) conditions.
Table I Human breast cancer cell lines: response to tirapazamine under aerobic or hypoxic conditions, activity of NADPH-dependent P450
reductase and ability to metabolise tirapazamine to the two-electron reduced product SR 4317 under hypoxic conditions
NADPH:P450 SR 4317 Western blot IC,sjLM' reduclase activity formation velocity densitometry
Aerobic Aerobic Hypoxic Differential nmol substrate reduced min-'mg-' values (arbitrary
Cell line exposure (96 h) exposure (3 h) exposure (3h) toxicityb lysate protein unijs)c
SKBr 3 10.4 ± 0.52 167.2 ± 48.2 5.1 ± 2.0 32.8 39.8 ± 3.2 22.4 ± 3.4 3187 ± 495
MDA-468 18.1 ± 7.0 180.9 ± 76.6 7.3 ± 2.1 24.9 20.5 ± 1.8 11.0 ± 1.9 1372 ± 251
T47D 20.9 5.3 301.3 ± 67.8 12.7 2.0 23.7 16.1 ± 3.2 13.2 2.7 1081 ± 253
MCF-7 (EP) 24.7 ± 9g9d 546.0 ± 61.3 15.0 ± 3.9 36.4 16.1 ± 1.2 10.2 ± 0.9 960 ± 136
ZR-75-1 26.6 3.6 1295 ± 502 18.9 2.4 68.5 10.8 ± 1.8 9.1 ± 1.4 473 ± 120
MDA-231 35.4 ± 4.1 307.8 ± 70.4 23.8 ± 4.0 12.9 6.9 ± 1.8 3.7 ± 0.7 231 ± 56
±Values_ s.d. updated from Patterson et al. (1994) with data being derived from up to five additional experiments on each cell line. bRatio of
ICso values for 3 h drug exposures under aerobic vs hypoxic conditions. 9Data derived from Western blots of three separate lysates of each cell
Line. dData from MCF-7 (LP), NADPH:P450 reductase activity = 18.7 ± 3.4nmol cytochromc c reduced min-' mg-' protein.
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Fugwe 2 Dependence of IC5o values, derived by MTT assay of
human breast cancer cells following 96 h exposure to tirap-
azamine in air, on NADPH cytochrome P450 reductase activity.
Bars indicate standard errors.
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Figwe 4 Western immunoblot of the relative NADPH cytoch-
rome P450 reductase expression in breast cancer cells ranked in
order of in vitro hypoxia sensitivity to tirapazamine. Gels were
loaded with equal protein concentrations oflysates from each cell
line. Microsomes derived from livers in phenobarbital-treated
mice were used as a positive control (67 zg of protein in 1I00id).
Phenobarbital was given at 80mgkg-' i.p. four times daily and
mice sacrificed 24 h after the last injection (Walton et al., 1992).
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Fue 5 Structure of tirapazamine (SR 4233) and its two-
electron reduced product SR 4317.
FugWe 3 Dependence of IC50 values of human breast cancer cells
exposed to tirapazamine for 3 h under aerobic (e) or hypoxic
(0) conditions on NADPH cytochrome P450 reductase activity.
Bars indicate standard errors.
icity (slope value= -1.10±0.12; P<10-IO). In contrast,
aerobic toxicity at 3 h does not show such a dependency
(slope value = - 1.34 ± 0.84;P= 0.19).
Further evidence for a relationship between P450 reductase
activity and acute hypoxic drug toxicity is provided by a
Western blotting experiment in which the levels of P450
reductase protein in the cell lines were measured usng a
specific NADPH-dependent P450 reductase antibody. This is
shown in Figure 4. An equivalent quantity of protein from
each cell line was loaded onto the gel in lanes from left to
right in rankl order of their sensitivity to tirapazamine. It is
apparent that the levels of P450 reductase protein decrease
from left to right, i.e. the lowest level of protein occurring in
the cell line with the greatest resstance to tirapazamine under
hypoxic conditions. Values of the densitometry readings from
these Western blots are given in Table I. When compared
with values of enzyme activity in each cell line there is a
strong correlation (slope ratio = 2.43 ± 0.32, P< 10-5).
P450 reductase has previously been shown to play an
important role in the metabolism of tirapazamine (Walton et
al., 1989, 1992; Lloyd et al., 1991; Wang et al., 1993). Fur-
thermore, the rate ofmetabolism has been linked to cytotoxic
effciency under anaerobic conditions (Biedermann et al.,
1991). In order to determine whether P450 reductase is a
major factor contributing to the metabolism of tirapazamine
in breast cancer cells, we have measured the rate at which cell
lysates reduce tirapazamine to its two-elctron reduced prod-
uct, SR 4317 under hypoxic conditions. The structures of
these compounds are given in Figure 5. No formation of the
deoxygenated four-eectron reduced product, SR 4330, was
deteced in these experiments. These rates offormation of SR
4317 are given in Table I and a plot of P450 reductase
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activity in the breast cancer cell lines vs the rate of SR 4317
formation catalysed by lysates ofeach cell line, with NADPH
provided as the electron source, is given in Figure 6. It can
be seen from these data that there is a strong correlation
(slope value=1.10±0.23; P=0.009) between P450 reduc-
tase activity and SR 4317 formation, with higher values of
enzyme activity resulting in greater rates of metabolism.
When similar experiments were carried out in air, no
metabolism was detected.
Previous studies have shown that tirapazamine is reductively
metabolised to SR 4317 by purified rat liver NADPH:
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cytochrome P450 reductase (Cahill and White. 1990; Fitz-
sinmons et al.. 1994). Lloyd et al. (1991) identified a free
radical intermediate formed during microsomal reduction of
tirapazamine and demonstrated. following the use of appro-
priate inhibitors, that P450 reductase was the enzyme respon-
sible for the radical production. In the present work it is
demonstrated that NADPH: cytochrome P450 reductase.
present in human breast cancer cell lines in vitro, plays a
major role in the reduction of tirapazamine and thus in
determining the toxicity of the drug. The relationship
between P450 reductase activity and drug toxicity is apparent
following exposure of cells to tirapazamine under hypoxic
conditions (3 h) and following 96 h exposure in air. However.
such a dependence is not apparent after only 3 h treatment in
air. These results can be interpreted on the basis of the
activation toxicity scheme outlined below.
le P450 reductase
" mediated
SR 4233 - SR 42'
°2
Potentially damaging
oxygen radicals
Hydrogen abstraction from
biomolecules - DNA lesion (toxic
- SR 4317
33-
Disproportionation
(1/2 SR 4233 -1/2 SR 4317i
In the presence of P450 reductase. tirapazamine (SR 4233)
will be subject to one-electron reduction to give the radical
anion (SR 4233- ). which in its protonated form has been
identified as a nitroxide radical (Lloyd et al.. 1991). In the
absence of oxygen the radical will either disproportionate
giving tirapazamine and SR 4317 (which can be regarded as
a detoxification reaction) or undergo reaction with bio-
molecules e.g. hydrogen atom abstraction from DNA (Baker
et al.. 1988). The latter reaction could yield a DNA radical
and SR 4317. There is some evidence to suggest that this
latter process is the first step in a type of chain reaction that
could result in multiple damaged sites from a single reductive
event. Laderoute et al. (1988) demonstrated the existence of a
short chain reaction during the radiolytic reduction of
tirapazamine in a solution containing formate. P Wardman
(personal communication) has suggested that SR 4233---
mediated hydrogen atom abstraction from the sugar back-
bone of DNA will result in strand breakage and the forma-
tion of a sugar radical and this radical can subsequently
reduce another molecule of tirapazamine etc.. thereby amp-
lifying the damage to DNA. It has been suggested that such
multiply damaged sites in DNA (which could be produced by
the mechanism described by Wardman) could be the cnrtical
lesions for tirapazamine toxicity (Brown. 1993). Therefore, if
the assumption is made that the breast cancer cell lines have
similar abilities to repair damage caused by SR 4233--, then
the level of damage under hypoxic conditions will be depen-
dent upon the rate at which SR 4233-- is formed, i.e. depen-
dent on the cellular activity of P450 reductase. Incidental
support for this comes from observations of Keohane et al.
(1990) who showed that tirapazamine was less toxic towards
a CHO cell line, designated MMCr, which is deficient in P450
reductase activity compared with the parental line from
which it was derived (CHO-KI).
A correlation between P450 reductase activity and cellular
sensitivity to tirapazamine is observed in air following
chronic (96 h) but not acute (3 h) exposure to the drug. This
difference and the difference between the values of IC50 for
acute hypoxic vs aerobic exposure (values of differential tox-
icity varying from 12.9 to 68.5) are most likely to be
explained by the effects of redox cycling which will occur in
air. During this process SR 4233- will be formed following
one-electron reduction of tirapazamine. catalysed by P450
reductase. In the presence of oxygen the reduced product will
be back-oxidised to tirapazamine. with the concomitant pro-
duction of oxygen radicals. Thus. in air, cellular damage may
be mediated by both superoxide radicals and SR 4233-.
Relatively high concentrations of tirapazamine were used
during the acute exposure to air. which is likely to result in
the formation of sufficiently high concentrations of oxygen
radicals to overwhelm cellular antioxidant defence mech-
amsms. Thus, the variation in cellular sensitivity to
tirapazamine following acute exposure in air may well reflect
variations in the tolerance of the different cell types both to
oxidative damage and to damage by SR 4233 -. thereby
explaining the apparent lack of a relationship between the
drug toxicity and P450 reductase activity under these condi-
tions. Evidence suggesting that the type of damage occumrng
in cells following acute (3 h) exposure to tirapazamine in
either air or nitrogen can be different. comes from studies
comparing drug toxicity in a V79 cell line and a DNA
repair-deficient mutant line derived from it (Keohane et al..
1990). V79 and irs-I cells have similar sensitivities to
tirapazamine in hypoxia whereas, in air irs- 1 cells are 10-fold
more sensitive (as measured by values of ICs9). The irs-I cells
are radiation sensitive and are defective in the fidelity of
DNA strand break repair. If it is assumed that the two cell
lines have a similar ability to metabolise tirapazamine i.e.,
similar P450 reductase activities, then the difference in sen-
sitivities between V79 and irs-I cells observed in air but not
in nitrogen would reflect differences in the damage caused
under these conditions. That is. in hypoxia. the damage is
caused by P450 reductase-mediated formation of tirap-
azamine radicals which can interact with DNA. whereas,
following acute exposures in air, cells are additionally
damaged by oxygen radicals. Support for the latter is
indicated by the finding that the addition of metal chelators
can protect cells against the toxic effects of tirapazamine in
air but not in nitrogen (Herscher et al.. 1994).
Following chronic (96 h) exposure of cells to tirapazamine
in air. a relationship between P450 reductase activity and
drug toxicity is observed. However, the concentrations of
drug used in these experiments were 10- to 50-fold lower than
those used in the acute (3 h) aerobic experiments. Therefore,
it might be expected that the concentrations of oxygen
radicals formed by redox cycling are likely to be low enough
to be accommodated by the cellular antioxidant defence
mechanisms. Thus. for this treatment condition, toxicity will
be due predominantly to damage caused by SR 4233-.
Lysates derived from the breast cancer cells have been
assayed for their ability to metabolise tirapazamine to SR
4317 under hypoxic conditions and this is shown to depend
on P450 reductase activity (Figure 5). Since conversion of
tirapazamine to its one-electron reduced product (SR 4233 -)
is enzyme mediated and, under hypoxic conditions, subse-
quent conversion to SR 4317 is a chemical process, we
believe that measurement of formation of SR 4317 is an
indirect measure of 'toxic' radical formation. Thus, it would
be expected that formation of SR 4317 by cell lysates should
correlate with the ICo for tirapazamine toxicity under
hypoxic conditions, which indeed is the case (slope value
=-0.93 ± 0.30. P = 0.036). Further, this correlation strong-
ly suggests that conversion of tirapazamine to SR 4317 by
direct two-electron reduction, e.g. by DT-diaphorase (which
will bypass the one-electron reduction product), does not
contribute to toxicity (Patterson et al.. 1994).
The level of hypoxia (Koch. 1993). the ability of cells to
repair DNA damage (Keohane et al.. 1990: Biedermann et
al.. 1991) and the level ofcellular reductases. will all influence
the therapeutic selectivity of tirapazamine. However, in
breast cancer cells the activity of NADPH:cytochrome P450
reductase is important for the hypoxic toxicity of
tirapazamine. In the application of these observations it is
useful to note that the expression of P450 reductase protein
(measured by immunoblot analysis) correlates well with the
activity of P450 reductase. indicating that the P450 reductase
protein is catalytically active. Thus, enzyme profiling of cells
and tissues, together with a measure of tumour hypoxia, may
provide a useful screen for predicting the activity of
tirapazamine in vivo (Philip et al., 1994; Rampling et al.,
1994). The work ofWang etal. (1993) and Biedermann etal.TwrinzinsKU-i4J kinmccwedb
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(1991) has shown that the hypoxic toxicity of tirapazamine
correlates with the overall rate of metabolism of the parent
drug. In a mouse and a human sarcoma cell line, DT-
diaphorase and cytochromes P450 were shown to contribute
to the metabolism of tirapazamine under hypoxic conditions
but no evidence was provided for the role of P450 reductase
in these cells (Wang et al., 1993). Our previous studies on
DT-diaphorase clearly indicate that this enzyme does not
play an important role in determining sensitivity to tirap-
azamine in air or hypoxia in the breast cancer cells (Patter-
son et al., 1994). The role of P450 isozymes is less clear,
particularly since cells in culture lose their ability to regulate
the expression of P450 genes (Paine, 1990). From studies
using chemical and antibody inhibitors in enzyme-induced
mouse liver microsomes, it has been suggested that Cyp2b
and Cyp2c can contribute to tirapazamine reduction (Riley et
al., 1993). However, this has yet to be linked to toxicity. In
clinical samples of breast tumour tissue only the presence of
CYPIA has been demonstrated unequivocally (Murray et al.,
1991), whereas in breast xenografts in mice CYPs 2A, 2B,
2C, 3A and 4A have been detected, but only to a significant
extent after enzyme induction (Smith et al., 1993).
In conclusion, we have demonstrated that NADPH:P450
reductase plays a major role in determining the hypoxic
toxicity of tirapazamine in breast cancer cells. This provides
an example of the enzyme-directed approach to bioreductive
drug development, and we are currently evaluating the
generaity of this approach for tirapazamine in other tumour
types.
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